Key Highlights

  • Shares are trading at $153.41 in pre-market activity, up 5.35% from Wednesday's close of $145.62.
  • Moderna and Merck said their personalized mRNA melanoma vaccine, intismeran autogene, met its primary endpoints in a Phase 3 trial.
  • Argus raised its price target on the stock to $180, while Rothschild & Co Redburn downgraded shares to Sell.
  • A Form 4 filing showed CEO Stephane Bancel sold nearly $11.7 million in shares on September 14.

Melanoma Vaccine Trial Success Extends Last Week's Rally

Moderna (NASDAQ:MRNA) shares rose further in pre-market trading Thursday, extending a rally that began last week when the company and Merck (NYSE:MRK) announced that their personalized mRNA melanoma vaccine, intismeran autogene, met its primary endpoints in a Phase 3 trial. Moderna is a Cambridge, Massachusetts-based biotechnology company that pioneers messenger RNA technology to develop vaccines and therapeutics across infectious disease, oncology, rare disease, and other therapeutic areas.

The trial result is viewed as a landmark validation of the mRNA oncology platform, having added tens of billions of dollars in combined Market Value for both companies since the announcement.

Analysts Remain Split Ahead of Upcoming Earnings

Investor enthusiasm is building further ahead of Moderna's upcoming quarterly report, even as analyst opinion remains divided. Argus raised its price target on the stock to $180, while Rothschild & Co Redburn downgraded shares to Sell, reflecting a wide range of views on how durable the recent rally can be.

CEO Share Sale Adds a Note of Caution

A Form 4 filing disclosed that Chief Executive Officer Stephane Bancel sold nearly $11.7 million in shares on September 14, a transaction some investors are weighing against the bullish trial news, even as the move also comes amid a broader healthcare sector uptick this week.

Outlook: Guidance Reiterated as Vaccine Demand Questions Persist

Moderna reiterated its 2026 Revenue growth guidance of up to 10% alongside the trial news, even as questions about long-term commercial demand for its core vaccine Franchise persist. Continued clinical progress on the mRNA oncology platform, together with the upcoming Earnings report, will likely be the next catalysts for the stock.